Scil Technology GmbH
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Scil Technology GmbH
Deals Update
A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.
Scil Technology assets bought out by Nanohale
Nanohale, a German firm developing new formulations of protein and peptide therapeutics, has acquired the R&D and contract development and manufacturing services assets of Scil Technology, bringing them into a new wholly owned subsidiary called Formycon.
Sanofi licenses regenerative osteoarthritis treatment from Scil
Sanofi has exclusively licensed Scil Technology's preclinical stage programme for a regenerative treatment of osteoarthritis and cartilage disorders.
Scil Technology appoints Christian Nafe to CEO
Scil Technology, the German protein drug development and formulation company, has appointed Christian Nafe, currently CFO of the company, to CEO. Mr Nafe succeeds Dr. Weishui Weiser, who retires after 5 years as managing director of Scil Technology.
Company Information
- Industry
-
Biotechnology
- Liposomes
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice